Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2020  |  Volume : 33  |  Issue : 4  |  Page : 1252-1257

Systemic anticoagulant in management of central retinal vein occlusion

Department of Opthalmology, Faculty of Medicine, Menoufia University, Menoufia, Egypt

Correspondence Address:
Aya E El-Absawy
MBBCh, Shebin El Kom, Menoufia
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/mmj.mmj_253_20

Rights and Permissions

Background Central retinal vein occlusion (CRVO) is one of the commonest retinal vascular diseases. Objective The aim was to compare between intravitreal injection of antivascular endothelial growth factors and combined intravitreal injection of antivasular endothelial growth factors with systemic anticoagulant drugs in treatment of CRVO. Patients and methods This study included 30 patients with CRVO who were divided into two groups. The first group was treated by intravitreal injection? of anti-Vascular endothelial growth factor (VEGF) (Ranibizumab) using three injections, 1 month apart. The second group was treated the same protocol of injection of the first group and systemic anticoagulant drugs, low-molecular-weight heparin. Optical coherence tomography was used to evaluate central macular thickness (CMT) at baseline and after treatment. Best-corrected visual acuity (BCVA) was documented before and after treatment. Results This study included 30 patients with CRVO. The first group treated by anti-VEGF (Ranibizumab) injection only improved in CMT from 702.9 ± 191.6 mm to 448.9 ± 178.0 mm (P = 0.001). BCVA also improved from 0.05 ± 0.01 to 0.11 ± 0.06 (P = 0.006). The second group treated by anti-VEGF (Ranibizumab) injection and systemic anticoagulant also improved in CMT from 814.4 ± 200.9 mm to 397.5 ± 166 mm (P = 0.001) and improved in BCVA from 0.06 ± 0.04 (range: 0.05–1.0) to 0.01 ± 0.11 (P = 0.002). Conclusion Systemic anticoagulant appears to be useful in the management of retinal vein occlusion regarding improvement in CMT and BCVA, but there is no difference regarding improvement between it and intravitreal injection of anti-VEGF (Ranibizumab).

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded22    
    Comments [Add]    

Recommend this journal